P.M. BRIEFING : Immunex Plans Product Line Switch
<i> From Times wire services</i>
NEW YORK —
Immunex Corp. today announced a plan that will transform it from a research-dominated firm in medical biotechnology into a conventional pharmaceutical company.
The 8-year-old company, based in Seattle, said it will achieve the transition primarily by reacquiring rights to sell Immunex-developed products in the United States. In return, its business partners will get rights to some other Immunex products, primarily for overseas distribution.
Immunex uses gene-splicing and other biotechnology techniques to create products for medical treatment.
